Current anti-influenza therapeutics and drugs in development are all directly targeted proteins encoded by the virus; for instance, oseltamivir inhibits NA, adamantanes block M2 ion channel, and the nucleoside analog favipiravir aims at RNA-dependent RNA polymerase (RdRP) (Goldhill et al., 2018). The gene discussed is XK; the disease is influenza.